EN
About Us
Chengdu MedGenCell Co., Ltd (hereafter referred to as "the Company") was established in 2015. It is a technology enterprise primarily engaged in the research and development of cutting-edge precision cell medicines and technical services. The company owns four GMP cell engineering rooms and quality control rooms.
The company developed the "world's first GMP-grade gene-edited T cell product" and collaborated with West China Hospital to complete the world's first clinical trial of gene-edited cells in humans. This achievement was featured on the front page of Nature magazine, which noted that it triggered a biotech competition between China and the United States. The complete Phase I clinical trial results were published in the journal Nature Medicine in 2020. In January 2024, the product received approval from the National Medical Products Administration (NMPA) for IND as a Class I cellular new drug. The Company is now proceeding with its commercialization efforts according to plan.
Company Honors：
In 2015, received the Chengdu Hi-Tech Zone Innovation and Entrepreneurship Talent Award;
In 2016, named Top Innovative and Entrepreneurial Team in Sichuan Province;
In 2017, honored with the title of Top Innovative and Entrepreneurial Team in Chengdu;
In 2018, recognized by Goldman Sachs as a "milestone event in Chinese life science and technology," and ranked among the top 50 'most investable and innovative Chinese companies' by Qingsci, SoftBank, and others;
In 2020, ranked second in the growth category of the Ninth China Precision Medicine Competition held by the Ministry of Science and Technology.
Evolution：
In 2014, the company’s founder, Dr. Dengtao, was brought back to China as an expert under Sichuan Province’s Thousand Talents Program to start a business;
The company was founded in 2015;
In 2016, the company collaborated with West China Hospital of Sichuan University to conduct the world's first clinical trial of a GMP-grade gene-edited T cell product "PD-1 Knockout Engineered T Cells for the Treatment of Advanced Non-Small Cell Lung Cancer: A Single-Arm, Open-Label, Prospective Phase I Clinical Study";
In 2017, our company received investment from the Sichuan Development Industrial Revitalization Fund;
In 2020, the results of the clinical trials conducted in collaboration with West China Hospital of Sichuan University were published in the journal Nature Medicine;
In 2024, the company’s core pipeline product "PD-1 Gene-Edited T Cell Injection" received IND approval for a Class I cellular new drug from the National Medical Products Administration.
